Cytokinetics Q1 2024 net loss $135.6M ($1.33 loss per share); cash $634M; aficamten NDA on track for Q3 2024

CYTOKINETICS INC

2024-Q1 EPS reported -$1.33 revenue$835,000

Net loss of $135.6M ($1.33 per share) vs $131.3M loss ($1.38 per share) in Q1 2023.
Cash and investments $634.3M as of March 31, 2024; revenue fell to $0.8M from $4.6M.
Aficamten NDA submission planned for Q3 2024; MAA submission to EMA in Q4 2024.
Initiated enrollment in pediatric HCM trial CEDAR-HCM; MAPLE-HCM enrollment expected to complete Q3 2024.
Appointed Sung Lee as EVP, CFO effective May 8, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYTOKINETICS INC reported first quarter of 2024 results: net income Net loss for the first quarter was $135.6 million, or $1.33 per share.

Period: first quarter of 2024
Net income: Net loss for the first quarter was $135.6 million, or $1.33 per share
Result: reported results

Exact text from the filing

Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-055610

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.